Intellectual Property India Publishes Patent Application for 'Anti-Bdca2 Antibody-Drug Conjugate And Use Thereof' Filed by Duality Biologics (SHANGHAI) Co. Ltd.

MUMBAI, India, Nov. 14 -- Intellectual Property India has published a patent application (202517069387 A) filed by Duality Biologics (SHANGHAI) Co. Ltd., Shanghai, on July 21, for 'anti-bdca2 antibody-drug conjugate and use thereof.'

Inventor(s) include Li, Xi; Zhang, Yu; Li, Bing; Hua, Haiqing; Zhu, Zhongyuan; and Li, Jian.

The application for the patent was published on Nov. 14, under issue no. 46/2025.

According to the abstract released by the Intellectual Property India: "An anti-BDCA2 antibody-drug conjugate and the use thereof. The anti-BDCA2 antibody-drug conjugate comprises: an antibody targeting BDCA2 or an antigen-binding fragment thereof, a linker fragment (L), and a glucocorticoid molecule. Also provided are a preparation method for and the use of the antibody-drug conjugate."

The patent application was internationally filed on Dec. 27, 2023, under International application No.PCT/CN2023/142457.

Disclaimer: Curated by HT Syndication.